Adma Biologics (ADMA) Assets Average (2011 - 2025)

Adma Biologics' Assets Average history runs 13 years deep, the most recent figure standing at $596.5 million for Q4 2025.

• Quarterly Assets Average rose 35.67% year-over-year to $596.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $596.5 million (up 35.67% YoY) and the FY2025 annual result came in at $556.5 million, up 36.08% from the prior year.
• Assets Average was $596.5 million for Q4 2025 at Adma Biologics, up from $563.5 million in the prior quarter.
• Across five years, Assets Average topped out at $596.5 million in Q4 2025 and bottomed at $221.7 million in Q1 2021.
• A 5-year average of $363.0 million and a median of $341.0 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2021 — Assets Average surged 94.8% — and 2024, when it dropped 1.33%.
• Adma Biologics' Assets Average stood at $257.4 million in 2021, then advanced by 26.05% to $324.5 million in 2022, then grew by 4.49% to $339.1 million in 2023, then climbed by 29.66% to $439.6 million in 2024, then jumped by 35.67% to $596.5 million in 2025.
• Business Quant data shows ADMA's Assets Average at $596.5 million in Q4 2025, $563.5 million in Q3 2025, and $534.5 million in Q2 2025.